Indication

Metastatic urothelial carcinoma

Metastatic urothelial carcinoma is an advanced malignancy arising from the specialized transitional epithelium that lines the urinary tract, most frequently originating in the urinary bladder, ureters, or renal pelvis. Read more about Metastatic urothelial carcinoma

0 drugs 0 manufacturers

Advertisement

Drugs that treat it

Common Metastatic urothelial carcinoma therapies.

0 drugs

No drugs are available

This indication does not currently contain public drugs.

Filter & compare in the drug finder →Opens the drug finder with Metastatic urothelial carcinoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Metastatic urothelial carcinoma.

Metastatic urothelial carcinoma is an advanced malignancy arising from the specialized transitional epithelium that lines the urinary tract, most frequently originating in the urinary bladder, ureters, or renal pelvis.

It predominantly affects older adults, occurring with higher incidence in males and individuals with a history of tobacco exposure.

Pathophysiologically, the disease is defined by primary malignant cells invading deep muscular layers and disseminating through vascular or lymphatic channels to distant anatomical sites, commonly including non-regional lymph nodes, the lungs, liver, and bones.

Clinically, it presents with hematuria, flank or pelvic pain, and systemic manifestations corresponding to the burden and distribution of secondary metastatic lesions.

Personalize your experience

Follow Metastatic urothelial carcinoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it